Skip to main content
Top
Published in: World Journal of Urology 12/2019

01-12-2019 | Prostate Cancer | Original Article

Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study

Authors: Luca Triggiani, Rosario Mazzola, Stefano Maria Magrini, Gianluca Ingrosso, Paolo Borghetti, Fabio Trippa, Andrea Lancia, Beatrice Detti, Giulio Francolini, Fabio Matrone, Roberto Bortolus, Giuseppe Fanetti, Ernesto Maranzano, Francesco Pasqualetti, Fabiola Paiar, Marco Lorenzo Bonù, Alessandro Magli, Alessio Bruni, Ercole Mazzeo, Ciro Franzese, Marta Scorsetti, Filippo Alongi, Barbara Alicja Jereczek-Fossa, Piet Ost, Michela Buglione

Published in: World Journal of Urology | Issue 12/2019

Login to get access

Abstract

Purpose

Herein, we report the clinical outcomes of a multicenter study evaluating the role of SBRT in a cohort of patients affected by oligoprogressive castration-resistant prostate cancer (CRPC).

Materials and methods

This is a retrospective multicenter observational study including eleven centers. Inclusion criteria of the current study were: (a) Karnofsky performance status > 80, (b) histologically proven diagnosis of PC, (c) 1–5 oligoprogressive metastases, defined as progressive disease at bone or nodes levels (detected by means of choline PET/CT or CT plus bone scan) during ADT, (d) serum testosterone level under 50 ng/ml during ADT, (e) controlled primary tumor, (f) patients treated with SBRT with a dose of at least 5 Gy per fraction to a biologically effective dose (BED) of at least 80 Gy using an alpha-to-beta ratio of 3 Gy, (g) at least 6 months of follow-up post-SBRT.

Results

Eighty-six patients for a total of 117 lesions were treated with SBRT. The median follow-up was 30.7 months (range 4–91 months). The median new metastasis-free survival after SBRT was 12.3 months (95% CI 5.5–19.1 months). One- and two-year distant progression-free survival was 52.3% and 33.7%, respectively. Twenty-six out of 86 patients underwent a second course of SBRT due to further oligoprogressive disease: This resulted in a median systemic treatment-free survival of 21.8 months (95% CI 17.8–25.8 months). One-year systemic treatment-free survival was 72.1%.

Conclusion

SBRT appears to be a promising approach in oligoprogressive castration-resistant prostate cancer. Further investigations are warranted.
Literature
1.
go back to reference Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration resistant prostate cancer. Eur Urol 71:630–642CrossRef Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration resistant prostate cancer. Eur Urol 71:630–642CrossRef
2.
go back to reference Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512CrossRef Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512CrossRef
3.
go back to reference Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148CrossRef Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148CrossRef
4.
go back to reference Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160CrossRef Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160CrossRef
5.
go back to reference Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433CrossRef Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433CrossRef
6.
go back to reference de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005CrossRef de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005CrossRef
7.
go back to reference Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992CrossRef Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992CrossRef
8.
go back to reference Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197CrossRef Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197CrossRef
9.
go back to reference Oudard S, Fizazi K, Sengeløv L et al (2017) Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol 35:3189–3197CrossRef Oudard S, Fizazi K, Sengeløv L et al (2017) Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol 35:3189–3197CrossRef
10.
go back to reference Triggiani L, Alongi F, Buglione M et al (2017) Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 116:1520–1525CrossRef Triggiani L, Alongi F, Buglione M et al (2017) Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 116:1520–1525CrossRef
11.
go back to reference Ost P, Bossi A, Decaestecker K et al (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67:852–863CrossRef Ost P, Bossi A, Decaestecker K et al (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67:852–863CrossRef
12.
go back to reference Fanetti G, Marvaso G, Ciardo D et al (2018) Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases. Med Oncol 35:75CrossRef Fanetti G, Marvaso G, Ciardo D et al (2018) Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases. Med Oncol 35:75CrossRef
13.
go back to reference Ponti E, Lancia A, Ost P et al (2017) Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy. Eur Urol Focus 3(6):538–544CrossRef Ponti E, Lancia A, Ost P et al (2017) Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy. Eur Urol Focus 3(6):538–544CrossRef
14.
go back to reference Jereczek-Fossa BA, Beltramo G et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82:889–897CrossRef Jereczek-Fossa BA, Beltramo G et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82:889–897CrossRef
15.
go back to reference Decaestecker K, De Meerleer G, Lambert B et al (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 9:135CrossRef Decaestecker K, De Meerleer G, Lambert B et al (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 9:135CrossRef
16.
go back to reference Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446–453CrossRef Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446–453CrossRef
17.
go back to reference De Bruycker A, Lambert B, Claeys T et al (2017) Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU Int 120:815–821CrossRef De Bruycker A, Lambert B, Claeys T et al (2017) Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU Int 120:815–821CrossRef
18.
go back to reference Wahl RL, Jacene H, Kasamon Y et al (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S–150SCrossRef Wahl RL, Jacene H, Kasamon Y et al (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S–150SCrossRef
19.
go back to reference Harris WP, Mostaghel EA, Nelson PS et al (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76–85CrossRef Harris WP, Mostaghel EA, Nelson PS et al (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76–85CrossRef
20.
go back to reference Boevé LMS, Hulshof MCCM, Vis AN et al (2018) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 75:410–418CrossRef Boevé LMS, Hulshof MCCM, Vis AN et al (2018) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 75:410–418CrossRef
21.
go back to reference Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353–2366CrossRef Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353–2366CrossRef
22.
go back to reference Palma DA, Haasbeek CJ, Rodrigues GB et al (2012) Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer 12:305CrossRef Palma DA, Haasbeek CJ, Rodrigues GB et al (2012) Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer 12:305CrossRef
23.
go back to reference Mazzola R, Fersino S, Ferrera G et al (2018) Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. Med Oncol 35(9):121CrossRef Mazzola R, Fersino S, Ferrera G et al (2018) Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. Med Oncol 35(9):121CrossRef
24.
go back to reference Correa RJ, Salama JK, Milano MT et al (2016) Stereotactic body radiotherapy for oligometastasis: opportunities for biology to guide clinical management. Cancer J 22(4):247–256CrossRef Correa RJ, Salama JK, Milano MT et al (2016) Stereotactic body radiotherapy for oligometastasis: opportunities for biology to guide clinical management. Cancer J 22(4):247–256CrossRef
25.
go back to reference Ost P, Jereczek-Fossa BA, Van As N, Zilli T et al (2016) Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol (R Coll Radiol) 28:e115–e120CrossRef Ost P, Jereczek-Fossa BA, Van As N, Zilli T et al (2016) Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol (R Coll Radiol) 28:e115–e120CrossRef
26.
go back to reference De Bari B, Alongi F, Lestrade L, Giammarile F (2014) Choline-PET in prostate cancer management: the point of view of the radiation oncologist. Crit Rev Oncol Hematol 91(3):234–247CrossRef De Bari B, Alongi F, Lestrade L, Giammarile F (2014) Choline-PET in prostate cancer management: the point of view of the radiation oncologist. Crit Rev Oncol Hematol 91(3):234–247CrossRef
27.
go back to reference Alongi F, Fersino S, Giaj Levra N et al (2015) Impact of 18F-choline PET/CT in the decision-making strategy of treatment volumes in definitive prostate cancer volumetric modulated radiation therapy. Clin Nucl Med 40(11):e496–e500CrossRef Alongi F, Fersino S, Giaj Levra N et al (2015) Impact of 18F-choline PET/CT in the decision-making strategy of treatment volumes in definitive prostate cancer volumetric modulated radiation therapy. Clin Nucl Med 40(11):e496–e500CrossRef
Metadata
Title
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study
Authors
Luca Triggiani
Rosario Mazzola
Stefano Maria Magrini
Gianluca Ingrosso
Paolo Borghetti
Fabio Trippa
Andrea Lancia
Beatrice Detti
Giulio Francolini
Fabio Matrone
Roberto Bortolus
Giuseppe Fanetti
Ernesto Maranzano
Francesco Pasqualetti
Fabiola Paiar
Marco Lorenzo Bonù
Alessandro Magli
Alessio Bruni
Ercole Mazzeo
Ciro Franzese
Marta Scorsetti
Filippo Alongi
Barbara Alicja Jereczek-Fossa
Piet Ost
Michela Buglione
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 12/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02717-7

Other articles of this Issue 12/2019

World Journal of Urology 12/2019 Go to the issue